Compare drug alternatives
Wegovy® Alternatives
Wegovy®(semaglutide) | Zepbound®(tirzepatide) |
|---|---|
Prescription Only | Prescription Only |
| Dosage & Administration | |
Administration | |
Subcutaneous. Learn more. | Subcutaneous. Learn more. |
Dosing | |
Initiate at 0.25 mg once weekly for 4 weeks. In 4 week intervals, increase the dose until a dose of 2.4 mg is reached. The maintenance dosage of WEGOVY® in adults is either 2.4 mg (recommended) or 1.7 mg once-weekly. Learn more. | Starting dosage is 2.5 mg injected subcutaneously once weekly. After 4 weeks, increase 5 mg once weekly. Increase the dosage in 2.5 mg increments after at least 4 weeks. Maintenance dosages are 5 mg, 10 mg, or 15 mg injected subcutaneously once weekly.. Learn more. |
Latin Shorthand | |
Begin at 0.25 mg qw for 4w. Increase by 4-week intervals until reaching 2.4 mg. The maintenance dosage for adults using WEGOVY® is either 2.4 mg (recommended) or 1.7 mg qw... Learn more. | The initial dose is 2.5 mg SQ q/week. After 4 weeks, increase to 5 mg q/week. Then, every 4 weeks, raise the dosage by 2.5 mg. Maintenance doses are either 5 mg, 10 mg, or 15 mg injected SQ q/week.. Learn more. |
| Financial Assistance | |
Out-Of-Pocket Costs With Copay Card | |
$0. Learn more. | $25. Learn more. |
Annual Cap | |
$225 per fill. Learn more. | $1,800. Learn more. |
Assistance Expiration | |
12/31/2023. Learn more. | 12/31/2024. Learn more. |
Generics | |
No lower-cost generic available | No lower-cost generic available |
| Physician Advisory | |
Adverse Reactions | |
Most common adverse reactions (incidence ≥ 5%) in adults
or pediatric patients aged 12 years and older are: nausea,
diarrhea, vomiting, constipation, abdominal pain, headache,
fatigue, dyspepsia, dizziness, abdominal distension, eructation,
hypoglycemia in patients with type 2 diabetes, flatulence,
gastroenteritis, gastroesophageal reflux disease, and
nasopharyngitis. . Learn more. | The most common adverse reactions, reported in ≥5% of patients treated with ZEPBOUND are: nausea, diarrhea, vomiting, constipation, abdominal pain, dyspepsia, injection site reactions, fatigue, hypersensitivity reactions, eructation, hair loss, gastroesophageal reflux disease.. Learn more. |
Mechanism of Actions (MoA) | |
GLP-1 Receptor Agonists. Learn more. | GLP-1 Receptor Agonists. Learn more. |
Special Populations | |
null null null null null null null null null null null null null null null null null null null null | Is there a pregnancy exposure registry for ZEPBOUND (tirzepatide)? Yes, there is a pregnancy exposure registry to monitor outcomes in pregnant women exposed to ZEPBOUND. Pregnant patients and healthcare providers can contact Eli Lilly and Company at 1-800-LillyRx (1-800-545-5979). What are the risks associated with ZEPBOUND during pregnancy? Weight loss is not recommended during pregnancy and discontinuation of ZEPBOUND is advised when pregnancy is recognized. Insufficient data exist to assess the risk of birth defects or miscarriage with tirzepatide use during pregnancy. Animal studies suggest potential fetal risks with exposure to tirzepatide. Are there clinical considerations for pregnant patients using ZEPBOUND? Pregnant patients, including those with obesity, should gain appropriate weight as required during pregnancy. Weight loss is not advised in pregnant patients. What animal data is available regarding tirzepatide exposure during pregnancy? Animal studies show fetal growth reductions and abnormalities in rats and rabbits given tirzepatide during pregnancy. These effects correlated with reductions in maternal body weights and food consumption. Is ZEPBOUND recommended during lactation? There is no data on tirzepatide's presence in animal or human milk. The benefits of breastfeeding should be weighed against any potential adverse effects of ZEPBOUND on the breastfed infant or maternal condition. Does ZEPBOUND impact oral hormonal contraceptives? ZEPBOUND may reduce the effectiveness of oral hormonal contraceptives due to delayed gastric emptying. Patients using these contraceptives should consider alternative or additional contraceptive methods for specific durations. What is known about ZEPBOUND's use in pediatric patients and the elderly? ZEPBOUND's safety and effectiveness have not been established in pediatric patients below 18 years old. In elderly patients (65 years and older), no significant differences were observed in safety or effectiveness compared to younger adults. Are dosage adjustments necessary for patients with renal or hepatic impairment? No dosage adjustment is recommended for patients with renal or hepatic impairment based on clinical studies, as no significant changes in tirzepatide pharmacokinetics were observed. |